Trastuzumab increases the sensitivity of HER2-amplified human gastric cancer cells to oxaliplatin and cisplatin by affecting the expression of telomere-associated proteins

HER2 amplification occurs in ~20% of gastric cancer (GC) cases; however, in gastric and gastroesophageal junction cancer with HER2 gene amplification, trastuzumab in combination with cisplatin (DDP)-based chemotherapy has been reported to improve the oncological outcome. The aim of the present study...

Descripción completa

Detalles Bibliográficos
Autores principales: LIU, YONGPING, LING, YANG, QI, QIUFENG, ZHU, MING, WAN, MEIZHEN, ZHANG, YAPING, ZHANG, CHANGSONG
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2015
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4301541/
https://www.ncbi.nlm.nih.gov/pubmed/25624920
http://dx.doi.org/10.3892/ol.2014.2793

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4301541/
https://www.ncbi.nlm.nih.gov/pubmed/25624920
http://dx.doi.org/10.3892/ol.2014.2793

Ejemplares similares